PTSM: Pharmaceutical Technology Sourcing and Management, Mar 2, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
PTSM: Pharmaceutical Technology Sourcing and Management, Mar 2, 2011
Biologics
The US Biosimilar Regulatory Scheme and Comparison with the European Experience: Where Do Where Go From Here?
By David Rosen , Larry Lian
The authors outline the key decision points FDA must consider in putting forth a US regulatory pathway for biosimilars.
Contract Manufacturing
A Roundup of Informex
By Patricia Van Arnum
Contract manufacturers and fine-chemical suppliers announce capacity expansions and service enhancements of Informex.
Outsourcing
Changes Underway for Biopharmaceutical Outsourcing
By Eric Langer
More crucial biomanufacturing operations are expected to be outsourced.
CSR and Sustainability Forum
Drug Development for Government, Nonprofit, and Developing-World Markets
By Chan Harjivan , George Dougherty
This article is Part I of a three-part series on biopharmaceutical issues in public health, government, and developing-world markets. Part 1 focuses on drug-development. Part II, which examines manufacturing, appeared in the April 2011 of Sourcing and Management. Part III, which analyzes distribution and administration,appeared in the May 2011 issue.
Bristol-Myers Squibb Moves Forward with HIV/AIDS Project in Africa
By Patricia Van Arnum
Bristol-Myers Squibb opens a new pediatric HIV/AIDS clinic in Tanzania.
CSR and Sustainability Forum
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here